Revenue Update on NeoGenomics(NASDAQ:NEO)

NeoGenomics(NASDAQ:NEO) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Jul 26, 2016. Company reported revenue of $63.13M. Analysts estimated a revenue of $61.07M. Earnings per share were $0.04. Analysts had estimated an EPS of $0.03.

In a different note, On May 11, 2016, Roth Capital said it Assumes its rating on NeoGenomics. The shares have been rated ‘Buy’ by the firm.

NeoGenomics (NEO) shares turned negative on Fridays trading session with the shares closing down -0.4 points or -4.39% at a volume of 3,94,105. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $9.01. The peak price level was also seen at $9.01 while the days lowest was $8.62. Finally the shares closed at $8.72. The 52-week high of the shares is $9.54 while the 52-week low is $5.26. According to the latest information available, the market cap of the company is $672 M.

Several Insider Transactions has been reported to the SEC. On May 27, 2016, Oort Douglas M Van (Chairman and CEO) sold 481,387 shares at $8.72 per share price.Also, On May 20, 2016, Steven A Ross (CIO) sold 18,000 shares at $8.50 per share price.On May 3, 2016, Steven C Jones (Executive VP of Finance) sold 177,745 shares at $8.21 per share price, according to the Form-4 filing with the securities and exchange commission.

NeoGenomics Inc. is an operator of a network of cancer-focused genetic testing laboratories. The Company offers testing services which includes Cytogenetics testing which is the study of normal and abnormal chromosomes and their relationship to disease; fluorescence in-situ hybridization (FISH) testing which is a branch of cancer genetics that focuses on detecting and locating the presence or absence of specific deoxyribonucleic acid (DNA) sequences and genes on chromosomes; flow cytometry testing which is a way to measure the characteristics of cell populations; immunohistochemistry (IHC) testing which is a process of identifying cell proteins in a tissue section utilizing the principle of antibodies binding specifically to in biological tissues. and molecular testing which is a cancer diagnostic tool focusing on the analysis of DNA and ribonucleic acid (RNA) as well as the structure and function of genes at a molecular level.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

NeoGenomics - Is it time to Sell?

Top Brokerage Firms are advising their investors on NeoGenomics. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.